Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy

Related Clinical Trial
SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy

Official Title

Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy

Brief Summary

      X-linked adrenoleukodystrophy (ALD) is a genetic disorder affecting the brain and adrenal
      glands. Approximately one third of boys who are at risk will develop cerebral disease. Using
      a specific diet and the compound Lorenzo's oil, it can be shown that very long chain fatty
      acids may be lowered in the blood, but it is not known to what degree that may prevent the
      onset of childhood disease.

      This proposal makes available Lorenzo's oil to individuals with ALD, a life threatening
      disorder for which there are presently no other therapies.
    

Detailed Description

      Expanded Access for Lorenzo's Oil in X-linked Adrenoleukodystrophy to Intermediate Size Group

      Introduction/Rationale: A diet that consists predominantly of long-chain monounsaturated
      fatty acids has been demonstrated to reduce the levels of very long chain fatty acids (VLCA)
      in individuals with X-linked adrenoleukodystrophy (ALD). VLCFA are the primary biochemical
      abnormality in this genetic disorder and have been implicated in the pathogenesis of the
      cerebral disease. It has been demonstrated in an open study that reduction of VLCFA for more
      than a year is protective for childhood cerebral disease.

      The purpose of this expanded access proposal is to transition an open label study presently
      ongoing in boys between the ages of 18 months and 13 years of age to an expanded access
      study. The reason for this transition is lack of funding for the investigator to continue to
      support this as a study. A study requires investigator involvement including the assistance
      of research associates to monitor and track outcomes, perform neuropsychological assessments,
      monitor adverse events, and coordinate periodic evaluations.

      A move to expanded access would decentralize the coordination and monitoring of evaluations
      which are clinically indicated even for participants who are not participating in a study.
      This role would be undertaken by the treating physician.

      Data collected in such an open study could serve as safety material for a later filing.

      Study Population:

        -  Males with X-linked adrenoleukodystrophy; see inclusion/exclusion criteria below.

      Procedure:

        1. Individuals who wish to obtain oil will submit clinical documentation of diagnosis to
           Dr. Gerald Raymond. This will be either elevated very long chain fatty acids (VLCFA) or
           DNA diagnosis of a mutation.

        2. Identify a provider who will be responsible for the supervision of the diet. It is
           suggested that this be an individual who is experienced in managing individuals on a
           special diets such as a biochemical geneticist or neurologist with experience in ALD.

        3. Studies required before prescription (It is important to emphasize that while many of
           the following are performed solely for the use of Lorenzo's oil, the costs of these
           investigations and consults will be the financial responsibility of the participants.)

             1. Baseline VLCFA, complete blood count with platelets, and comprehensive metabolic
                panel

             2. Nutrition consult with a determination of daily calories. Thirty percent of
                calories will be provided by lipids and 2/3 of these lipid calories will be
                provided by long chain monounsaturated fatty acids (Lorenzo's oil). This
                nutritional evaluation will include the following.

           i. Present body parameters including weight, height, and BMI ii. Calculated daily
           calories and other nutritional needs for growth. iii. Calculation of percent of diet as
           lipids and amount of oil to be consumed daily iv. Instruction in diet restriction and
           monitoring of said diet. v. Recommend supplements. vi. Instructions in providing diet
           recall vii. Suggestions for maintaining and improving compliance. c. An MRI and adrenal
           testing are clinically indicated and will be required as part of expanded access.

        4. Clinical research forms (CRF) will be designed for the baseline and follow up
           information for uniformity of documentation.

        5. Upon receipt of this information, Dr. Raymond will provide an authorization of the
           prescription to the supplier, Nutricia N.A.

        6. Monitoring while receiving oil will consist of the following

             1. VLCFA; Complete blood count (CBC), and Comprehensive metabolic panel every 3 months

             2. Nutrition consult yearly.

             3. Magnetic Resonance Imaging of the brain will be performed every 6-12 months

             4. Appropriate monitoring of adrenal function.

             5. CRFs' will be forwarded every three months for all active participants on a
                January, April, July, October schedule

             6. The identified provider will be responsible for providing this information to Dr.
                Raymond's office. Failure to provide this information will result in withholding of
                authorization and no dispensing of the product.

             7. No more than 3 months' supply of the product will be authorized or shipped at a
                time.

             8. In the event of development of thrombocytopenia, Lorenzo's oil will be suspended
                and glyceryl trioleate (GTO) substituted for one month and then reintroduced as
                half dose of Lorenzo's oil followed by incremental increases as tolerated. We have
                previously used 80,000 platelets as a lower limit and would recommend this as
                providing an adequate margin of safety.

        7. Adverse events will be tracked and if resulting in hospitalization or death will be
           reported as required to the sponsor and FDA in the required period of time.

      Otherwise all reported adverse events will be tabulated and reported in the yearly IND
      report.

      Adverse events will include conversion of normal MRIs to those demonstrating cerebral disease
      and any interventions including bone marrow transplantation or gene therapy which are
      presently the only options to halt cerebral disease.
    


Study Type

Expanded Access




Condition

X-linked Adrenoleukodystrophy

Intervention

Lorenzo's Oil


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug





Eligibility Criteria

        Inclusion Criteria:

          -  Males with X-linked adrenoleukodystrophy as determined by biochemical or genetic
             determination.

          -  Greater than 18 months of age through 18 years of age

          -  Normal cerebral MRI at baseline.

        Exclusion Criteria:

          -  Medical issues which preclude the administration of Lorenzo's oil
      

Gender

Male

Ages

18 Months - 18 Years


Contacts

Gerald V Raymond, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02233257

Organization ID

1401M47561


Responsible Party

Sponsor

Study Sponsor

University of Minnesota


Study Sponsor

Gerald V Raymond, MD, Principal Investigator, University of Minnesota


Verification Date

January 2018